Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1990 Jun;87(11):4275–4279. doi: 10.1073/pnas.87.11.4275

Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro.

H Ito 1, S C Miller 1, M E Billingham 1, H Akimoto 1, S V Torti 1, R Wade 1, R Gahlmann 1, G Lyons 1, L Kedes 1, F M Torti 1
PMCID: PMC54091  PMID: 2349236

Abstract

The anthracycline antibiotic doxorubicin produces a characteristic myopathy in cardiac muscle that limits its use in cancer therapy. We have shown in cultured neonatal rat cardiac muscle cells that doxorubicin treatment resulted in a rapid, selective decrease in the expression of muscle-specific genes, which preceded other changes characteristic of doxorubicin cardiomyopathy. Doxorubicin selectively and dramatically decreased the levels of mRNA for the sarcomeric genes, alpha-actin, troponin I, and myosin light chain 2, as well as the muscle-specific, but nonsarcomeric M isoform of creatine kinase. However, doxorubicin did not affect nonmuscle gene transcripts (pyruvate kinase, ferritin heavy chain, and beta-actin). Actinomycin D, an inhibitor of DNA-dependent RNA polymerase, did not show a similar selective decrease of muscle-specific mRNAs but, rather, produced a nonspecific, dose-dependent decrease of muscle and nonmuscle transcripts. The doxorubicin effect on muscle gene expression was limited to cardiac muscle; cultured skeletal myocytes were resistant to the effects of doxorubicin at 100-fold greater doses than those causing changes in mRNA levels in cardiac muscle cells. These effects of doxorubicin were reproduced in vivo; rats injected with doxorubicin showed a dose-dependent decrease in the levels of mRNAs for alpha-actin, troponin I, myosin light chain 2, and M isoform of creatine kinase in cardiac but not skeletal muscle. These selective changes in gene expression in cardiocyte cultures and cardiac muscle precede classical ultrastructural changes and may explain the myofibrillar loss that characterizes doxorubicin cardiac injury.

Full text

PDF
4276

Images in this article

4276Image
on p.4276
4276Image
on p.4276
4276Image
on p.4276
4276Image
on p.4276
4276Image
on p.4276
4276Image
on p.4276
4276Image
on p.4276
4277Image
on p.4277
4277Image
on p.4277
4277Image
on p.4277
4278Image
on p.4278
4278Image
on p.4278
4278Image
on p.4278
4278Image
on p.4278

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bachur N. R., Gordon S. L., Gee M. V. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol. 1977 Sep;13(5):901–910. [PubMed] [Google Scholar]
  2. Billingham M. E., Mason J. W., Bristow M. R., Daniels J. R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978 Jun;62(6):865–872. [PubMed] [Google Scholar]
  3. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. doi: 10.1021/bi00591a005. [DOI] [PubMed] [Google Scholar]
  4. Doroshow J. H. Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun. 1986 Feb 26;135(1):330–335. doi: 10.1016/0006-291x(86)90981-2. [DOI] [PubMed] [Google Scholar]
  5. Feinberg A. P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6–13. doi: 10.1016/0003-2697(83)90418-9. [DOI] [PubMed] [Google Scholar]
  6. Gunning P., Mohun T., Ng S. Y., Ponte P., Kedes L. Evolution of the human sarcomeric-actin genes: evidence for units of selection within the 3' untranslated regions of the mRNAs. J Mol Evol. 1984;20(3-4):202–214. doi: 10.1007/BF02104727. [DOI] [PubMed] [Google Scholar]
  7. Harris P. A., Gross J. F. Preliminary pharmacokinetic model for adriamycin (NSC-123127). Cancer Chemother Rep. 1975 Jul-Aug;59(4):819–825. [PubMed] [Google Scholar]
  8. Jaenke R. S. An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest. 1974 Mar;30(3):292–304. [PubMed] [Google Scholar]
  9. Lampidis T. J., Henderson I. C., Israel M., Canellos G. P. Structural and functional effects of adriamycin on cardiac cells in vitro. Cancer Res. 1980 Nov;40(11):3901–3909. [PubMed] [Google Scholar]
  10. Legha S. S., Benjamin R. S., Mackay B., Ewer M., Wallace S., Valdivieso M., Rasmussen S. L., Blumenschein G. R., Freireich E. J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982 Feb;96(2):133–139. doi: 10.7326/0003-4819-96-2-133. [DOI] [PubMed] [Google Scholar]
  11. Lewis W., Gonzalez B. Actin isoform synthesis by cultured cardiac myocytes. Effects of doxorubicin. Lab Invest. 1987 Mar;56(3):295–301. [PubMed] [Google Scholar]
  12. Lewis W., Gonzalez B. Anthracycline effects on actin and actin-containing thin filaments in cultured neonatal rat myocardial cells. Lab Invest. 1986 Apr;54(4):416–423. [PubMed] [Google Scholar]
  13. Miller S. C., Ito H., Blau H. M., Torti F. M. Tumor necrosis factor inhibits human myogenesis in vitro. Mol Cell Biol. 1988 Jun;8(6):2295–2301. doi: 10.1128/mcb.8.6.2295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Myers C. E., McGuire W. P., Liss R. H., Ifrim I., Grotzinger K., Young R. C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977 Jul 8;197(4299):165–167. doi: 10.1126/science.877547. [DOI] [PubMed] [Google Scholar]
  15. Ng S. Y., Gunning P., Eddy R., Ponte P., Leavitt J., Shows T., Kedes L. Evolution of the functional human beta-actin gene and its multi-pseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes. Mol Cell Biol. 1985 Oct;5(10):2720–2732. doi: 10.1128/mcb.5.10.2720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Olson R. D., Mushlin P. S., Brenner D. E., Fleischer S., Cusack B. J., Chang B. K., Boucek R. J., Jr Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A. 1988 May;85(10):3585–3589. doi: 10.1073/pnas.85.10.3585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Perryman M. B., Kerner S. A., Bohlmeyer T. J., Roberts R. Isolation and sequence analysis of a full-length cDNA for human M creatine kinase. Biochem Biophys Res Commun. 1986 Nov 14;140(3):981–989. doi: 10.1016/0006-291x(86)90732-1. [DOI] [PubMed] [Google Scholar]
  18. Silberstein L., Webster S. G., Travis M., Blau H. M. Developmental progression of myosin gene expression in cultured muscle cells. Cell. 1986 Sep 26;46(7):1075–1081. doi: 10.1016/0092-8674(86)90707-5. [DOI] [PubMed] [Google Scholar]
  19. Simpson P., Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ Res. 1982 Jan;50(1):101–116. doi: 10.1161/01.res.50.1.101. [DOI] [PubMed] [Google Scholar]
  20. Singal P. K., Deally C. M., Weinberg L. E. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987 Aug;19(8):817–828. doi: 10.1016/s0022-2828(87)80392-9. [DOI] [PubMed] [Google Scholar]
  21. Someya A., Akiyama T., Misumi M., Tanaka N. Interaction of anthracycline antibiotics with actin and heavy meromyosin. Biochem Biophys Res Commun. 1978 Dec 29;85(4):1542–1550. doi: 10.1016/0006-291x(78)91178-6. [DOI] [PubMed] [Google Scholar]
  22. Torti F. M., Bristow M. R., Howes A. E., Aston D., Stockdale F. E., Carter S. K., Kohler M., Brown B. W., Jr, Billingham M. E. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983 Dec;99(6):745–749. doi: 10.7326/0003-4819-99-6-745. [DOI] [PubMed] [Google Scholar]
  23. Torti S. V., Kwak E. L., Miller S. C., Miller L. L., Ringold G. M., Myambo K. B., Young A. P., Torti F. M. The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene. J Biol Chem. 1988 Sep 5;263(25):12638–12644. [PubMed] [Google Scholar]
  24. Von Hoff D. D., Layard M. W., Basa P., Davis H. L., Jr, Von Hoff A. L., Rozencweig M., Muggia F. M. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710–717. doi: 10.7326/0003-4819-91-5-710. [DOI] [PubMed] [Google Scholar]
  25. Webster K. A. Regulation of glycolytic enzyme RNA transcriptional rates by oxygen availability in skeletal muscle cells. Mol Cell Biochem. 1987 Sep;77(1):19–28. doi: 10.1007/BF00230147. [DOI] [PubMed] [Google Scholar]
  26. Young R. C., Ozols R. F., Myers C. E. The anthracycline antineoplastic drugs. N Engl J Med. 1981 Jul 16;305(3):139–153. doi: 10.1056/NEJM198107163050305. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES